| Study outcome | Abatacept | Control |
| n = 258 | n = 133 | |
| Female | 77.1% | 79.7% |
| Age (years) | 53.5 (12.4) | 52.7 (11.3) |
| Tender joint count | 31.2 (13.0) | 32.8 (13.4) |
| Swollen joint count | 22.3 (10.2) | 22.0 (10.0) |
| Patient global assessment | 69.2 (19.7) | 69.7 (20.3) |
| Physician global assessment | 68.8 (17.7) | 67.3 (16.8) |
| Pain assessment | 70.8 (19.8) | 69.6 (19.0) |
| HAQ | 1.8 (0.6) | 1.8 (0.6) |
| C reactive protein | 45.6 (39.5) | 40.4 (36.2) |
| ESR | 51.3 (29.0) | 47.1 (26.9) |
| n = 256 | n = 131 | |
| Activity limitation (0–30 days) | 17.3 (11.1) | 15.9 (11.2) |
| Fatigue (0–100 VAS) | 73.5 (20.0) | 72.2 (19.3) |
| Sleep quality (0–100) | 48.9 (19.0) | 45.9 (18.4) |
| SF-36 (0–100) | ||
| SF-36 Physical functioning | 26.1 (8.9) | 26.4 (8.4) |
| SF-36 Role-physical | 30.5 (6.2) | 31.9 (6.8) |
| SF-36 Bodily pain | 30.6 (6.7) | 31.3 (6.6) |
| SF-36 General health | 34.8 (9.3) | 35.0 (8.5) |
| SF-36 Vitality | 35.0 (8.5) | 36.7 (9.0) |
| SF-36 Social functioning | 33.3 (10.8) | 33.8 (11.5) |
| SF-36 Role-emotional | 35.8 (13.7) | 36.9 (13.8) |
| SF-36 Mental health | 40.6 (12.7) | 42.8 (11.1) |
| SF-36 Physical component | 27.5 (6.9) | 27.8 (6.3) |
| SF-36 Mental component | 41.3 (12.4) | 42.9 (11.9) |
Values are mean (SD).
ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; SF-36, short form 36 item health survey; VAS, visual analogue scale.